Banner background image

DISCOVER MORE ABOUT LEQVIO®

Browse our gallery of educational
resources to get to know LEQVIO
even
better through video content and
downloadable infographics

Catch up on the highlights from LEQVIO: A Bold Way Forward

Watch the videos below for key takeaways from a 2-part LEQVIO CONNECT event,
featuring leaders and experts in cardiovascular health

Body background image

LEQVIO: A Bold Way Forward

In this overview presentation, learn about what makes LEQVIO clinical profile and dosing different.

WATCH 1648101222 1_bfwncktg
Body background image

Unmet Need in Patients With ASCVD

Dr Pam Taub and Dr Alan S. Brown provide insights on the state of cardiovascular disease and what makes LEQVIO such a vital treatment option for certain patients with ASCVD.

WATCH 1648020944 1_tgdxoad1
Body background image

Lowering LDL-C With LEQVIO: Clinical Trial Data Overview

Dr Alan S. Brown dives deeper into pivotal phase III clinical trial data for LEQVIO, for patients with ASCVD, with a focus on efficacy and safety.

WATCH 1648020553 1_xdv2fzbe
Body background image

Dosing and Administration: How to Give LEQVIO to Your Patients

Dr Alan S. Brown shares details on the LEQVIO dosing regimen—two doses a year after the first year—while highlighting other key information, including product storage, handling, and administration.1

WATCH 1648020356 1_chjn6u8e
Body background image

Patients Who Could Benefit From LEQVIO

Dr Pam Taub and Dr Alan S. Brown describe a few types of patients from their clinics who are struggling to achieve the recommended LDL-C target with diet and statin therapy and could benefit from additional treatment options.

WATCH 1648020145 1_ze2rk93k
Body background image

LEQVIO via Buy-and-Bill With In-Office Administration

Find out more about acquiring HCP-administered products like LEQVIO through Buy-and-Bill, the primary method for specialty drugs covered under the medical benefit.

WATCH 1648019958 1_jkzyoboy
Body background image

LEQVIO via Referral to an Alternate Injection Center (AIC)

If Buy-and-Bill is not your method of choice for acquiring LEQVIO, get details on how you can refer patients to an AIC to handle ordering, administration, and reimbursement. Visit LEQVIO-locator.com to find an AIC.

WATCH 1648019710 1_0y2f5bpm
Body background image

LEQVIO via Specialty Pharmacy

Gain insights into a third acquisition option for patients to acquire LEQVIO: a specialty pharmacy for in-office administration.

WATCH 1648018871 1_lngn2u2g
Body background image

LEQVIO Billing and Coding Information

Learn more about best practices for billing, coding, and reimbursement for HCP-administered products like LEQVIO with Bobbi Buell.

WATCH 1648018476 1_fhu8obrw
Body background image

Recap the LEQVIO
Clinical
Story On-the-Go

Take a moment for a refresh of the entire LEQVIO
clinical story with insights into efficacy, dosing,
safety, and more!

WATCH play
1648100806 1_lxunae4a

Learn more about what makes LEQVIO different

Download the infographics below to find out even more about LEQVIO

Body background image

LEQVIO: From Discovery to Development

DOWNLOAD https://novartispharma.widen.net/s/rzvj2qdc2z/164659-leq-from-discovery-to-development-infographic-12.21
Body background image

ORION-10 Clinical Trial Design

DOWNLOAD https://novartispharma.widen.net/s/mwv5kj5xfm/158721-leq-clinical-trial-design-infographic-12.21
Body background image

Discover Clinical Efficacy & Safety

DOWNLOAD https://novartispharma.widen.net/s/8jfmsjtd5w/159040-leq-clinical-trial-efficacy-and-safety-infographic-12.21
Body background image

Explore the MOA

DOWNLOAD https://novartispharma.widen.net/s/gkgbqzjzcr/164678-leq-harnessing-the-natural-process-of-rnai-to-lower-ldl-c-in-certain-patients-with-ascvd-infographic-12.21
Body background image

Dive Into siRNA Technology

DOWNLOAD https://novartispharma.widen.net/s/q5hqn8jsbk/164671-leq-a-small-interfering-rna-therapy-that-selectively-targets-the-liver-to-regulate-ldl-c-levels-infographic-12.21
THERE'S MORE TO KNOW ABOUT LEQVIO

Discover what makes LEQVIO dosing different

DIVE INTO DOSING arrow

AIC, alternate infusion center; ASCVD, atherosclerotic cardiovascular disease; MOA, mechanism of action; siRNA, small interfering RNA.

INDICATION AND IMPORTANT
SAFETY INFORMATION

COLLAPSE

EXPAND

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Limitations of Use: The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.

Adverse reactions led to discontinuation in 2.5% and 1.9% of LEQVIO- and placebo-treated patients, respectively. Discontinuation due to injection site reactions, which included injection site pain, erythema and rash, were 0.2% and 0% of LEQVIO- and placebo-treated patients, respectively.

Please click here for LEQVIO full Prescribing Information.

References: 1. LEQVIO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021. 2. Cubanski J, Damico A, Neuman T, Jacobson G. Sources of supplemental coverage among Medicare beneficiaries in 2016. KFF. November 28, 2018. Accessed November 5, 2021. https://www.kff.org/medicare/issue-brief/sources-of-supplemental-coverage-among-medicare-beneficiaries-in-2016/# 3. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 4. Data on file. Novartis Pharmaceuticals Corp; 2019. 5. Grundy SM, Stone NJ, Bailey AL, et al. AHN/AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 8. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 9. Jacobson T, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(6):405-424. 10. Jones PH, Radhika N, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 11. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 12. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/j.jacl.2016.06.011

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Limitations of Use: The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.

Adverse reactions led to discontinuation in 2.5% and 1.9% of LEQVIO- and placebo-treated patients, respectively. Discontinuation due to injection site reactions, which included injection site pain, erythema and rash, were 0.2% and 0% of LEQVIO- placebo-treated patients, respectively.

Please click here for LEQVIO full Prescribing Information.

References: 1. LEQVIO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021. 2. Cubanski J, Damico A, Neuman T, Jacobson G. Sources of supplemental coverage among Medicare beneficiaries in 2016. KFF. November 28, 2018. Accessed November 5, 2021. https://www.kff.org/medicare/issue-brief/sources-of-supplemental-coverage-among-medicare-beneficiaries-in-2016/# 3. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 4. Data on file. Novartis Pharmaceuticals Corp; 2019. 5. Grundy SM, Stone NJ, Bailey AL, et al. AHN/AHA/ACC/AACVPR/AAPA/ABC/ACPM/
ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 8. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 9. Jacobson T, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(6):405-424. 10. Jones PH, Radhika N, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 11. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 12. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/j.jacl.2016.06.011